Review anchor
Alpha-2A adrenergic receptor
SINGLE PROTEIN · Homo sapiens
As of 2026-09-14
Evidence Snapshot
Alpha-2A adrenergic receptor
CHEMBL1867
SINGLE PROTEIN
Homo sapiens
Identity Layer
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Alpha-2A adrenergic receptor as ChEMBL target CHEMBL1867, mapped to UniProt P08913. Disease framing currently uses the Open Targets-ready proxy contract.
ChEMBL target ID
CHEMBL1867
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine
As of 2026-09-14
www.ebi.ac.uk
UniProt accession
P08913
Alpha-2A adrenergic receptor
UniProt accession via ChEMBL component mapping
As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy
As of 2026-09-14
www.ebi.ac.uk
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Review-ready Target Rationale
Why Alpha-2A adrenergic receptor matters
Alpha-2A adrenergic receptor is reviewed as Alpha-2A adrenergic receptor (UniProt P08913); the current evidence base includes 214 approved drugs, 4224 compounds, and 606 assays, with lead potency reaching pChEMBL 10.6.
Protein context
Alpha-2A adrenergic receptor
Alpha-2A adrenergic receptor Sequence length is 465 aa.
Review this target as Alpha-2A adrenergic receptor, mapped to UniProt P08913. Sequence length is 465 aa.
Protein source · UniProt accession via ChEMBL component mapping
UniProt P08913
Protein
Disease context
Disease signal
Disease relevance is not yet populated for this evidence card.
This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target recordActivity base
Portfolio and assay base
ChEMBL currently tracks 214 approved drugs, 4224 compounds, and 606 assays for this target. The dominant activity type is KI. CHEMBL1256414 is the current potency anchor at pChEMBL 10.6.
Use CHEMBL1256414 as the tractability anchor when discussing potency (pChEMBL 10.6).
Activity source · ChEMBL 36 via Core Engine
214 approved
pChEMBL 10.6
Source Guidance
Start with the right source
Pick the first block or linked source that matches the review question in front of you.
Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution
Start with the review rationale when you need to explain why Alpha-2A adrenergic receptor matters before drilling into raw source blocks.
Jump to Review RationaleNeed stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping
Go back to the target snapshot when you need the naming and mapping contract behind UniProt P08913, not just the summarized rationale.
Open Protein ContextNeed disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy
Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
4224
Total Compounds
606
Total Assays
214
Approved Drugs
IC50: 1051.0, KI: 1973.0, EC50: 252.0, KD: 10.0
Activity Types
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL1256414
|
10.6 | Ki | — |
|
|
No preferred name
CHEMBL4482861
|
10.4 | Ki | — |
|
|
No preferred name
CHEMBL4536304
|
10.3 | Ki | — |
|
|
No preferred name
CHEMBL4438801
|
10.2 | Ki | — |
|
|
No preferred name
CHEMBL176261
|
10.0 | Ki | — |
Approved Drugs
| Structure | Compound | First Approval |
|---|---|---|
|
|
LOFEXIDINE
CHEMBL17860
|
2018 |
|
|
BREXPIPRAZOLE
CHEMBL2105760
|
2015 |
|
|
SILODOSIN
CHEMBL24778
|
2008 |
|
|
PALIPERIDONE
CHEMBL1621
|
2006 |
|
|
ARIPIPRAZOLE
CHEMBL1112
|
2002 |
|
|
KETOTIFEN
CHEMBL534
|
1999 |
|
|
DEXMEDETOMIDINE HYDROCHLORIDE
CHEMBL2106195
|
1999 |
|
|
DEXMEDETOMIDINE
CHEMBL778
|
1999 |
|
|
QUETIAPINE
CHEMBL716
|
1997 |
|
|
PRAMIPEXOLE
CHEMBL301265
|
1997 |
|
|
TAMSULOSIN
CHEMBL836
|
1997 |
|
|
RALOXIFENE
CHEMBL81
|
1997 |
|
|
TIZANIDINE
CHEMBL1079
|
1996 |
|
|
BRIMONIDINE
CHEMBL844
|
1996 |
|
|
OLANZAPINE
CHEMBL715
|
1996 |
|
|
CABERGOLINE
CHEMBL1201087
|
1996 |
|
|
MIRTAZAPINE
CHEMBL654
|
1996 |
|
|
TIZANIDINE HYDROCHLORIDE
CHEMBL1200329
|
1996 |
|
|
CARVEDILOL
CHEMBL723
|
1995 |
|
|
RISPERIDONE
CHEMBL85
|
1993 |
|
|
CISAPRIDE
CHEMBL1729
|
1993 |
|
|
AMLODIPINE
CHEMBL1491
|
1992 |
|
|
SERTRALINE
CHEMBL809
|
1991 |
|
|
TICLOPIDINE
CHEMBL833
|
1991 |
|
|
MOXONIDINE
CHEMBL19236
|
1991 |
|
|
EBASTINE
CHEMBL305660
|
1990 |
|
|
DOXAZOSIN
CHEMBL707
|
1990 |
|
|
CLOZAPINE
CHEMBL42
|
1989 |
|
|
SELEGILINE
CHEMBL972
|
1989 |
|
|
CLOMIPRAMINE
CHEMBL415
|
1989 |
|
|
PERGOLIDE
CHEMBL531
|
1988 |
|
|
RILMENIDINE
CHEMBL289480
|
1987 |
|
|
TERCONAZOLE
CHEMBL1714574
|
1987 |
|
|
APRACLONIDINE
CHEMBL647
|
1987 |
|
|
FLUOXETINE
CHEMBL41
|
1987 |
|
|
TERAZOSIN
CHEMBL611
|
1987 |
|
|
OXYMETAZOLINE
CHEMBL762
|
1986 |
|
|
OXYMETAZOLINE HYDROCHLORIDE
CHEMBL1200791
|
1986 |
|
|
GUANFACINE HYDROCHLORIDE
CHEMBL1200494
|
1986 |
|
|
GUANFACINE
CHEMBL862
|
1986 |
|
|
AMIODARONE
CHEMBL633
|
1985 |
|
|
PENTAMIDINE
CHEMBL55
|
1984 |
|
|
MORPHINE
CHEMBL70
|
1984 |
|
|
GUANABENZ
CHEMBL420
|
1982 |
|
|
CYCLIZINE
CHEMBL648
|
1982 |
|
|
GENTIAN VIOLET
CHEMBL64894
|
1982 |
|
|
HALOPROGIN
CHEMBL1289
|
1982 |
|
|
VERAPAMIL
CHEMBL6966
|
1981 |
|
|
TRAZODONE
CHEMBL621
|
1981 |
|
|
AMOXAPINE
CHEMBL1113
|
1980 |
Source Header